< Back to previous page
Researcher
Timothy Devos
- Disciplines:Immunology
Affiliations
- Molecular Immunology (Rega Institute) (Lab)
Member
From1 Jan 2019 → Today - Tracheal Transplantation (Lab)
Member
From1 Jan 2012 → 31 Dec 2018 - Nephrology and Renal Transplantation Research Group (Division)
Member
From1 Oct 2001 → 30 Sep 2005
Projects
1 - 4 of 4
- Identifying neutrophilic granulocytes as key contributors and therapeutic targets in the development and progression of BCR::ABL1 negative myeloproliferative neoplasms.From4 Oct 2023 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Kidney stem/progenitor cells as a potent source for kidney-targeted cell therapyFrom1 Oct 2021 → TodayFunding: Fund Recuperation Fiscal Exemption, BOF - projects
- Kidney stem/progenitor cells as a potent source for kidney-targeted cell therapy.From22 Sep 2021 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Restoring tissue regeneration in patients with visceral Graft versus Host Disease.From1 Jan 2015 → 31 Dec 2021Funding: H2020 - Health, demographic change and wellbeing
Publications
1 - 10 of 122
- Ruxolitinib in patients with polycythemia vera resistant and/or intolerant to hydroxyurea: European observational study(2024)
Authors: Timothy Devos
Pages: 379 - 391 - Changes in bone marrow fibrosis during momelotinib or ruxolitinib therapy do not correlate with efficacy outcomes in patients with myelofibrosis.(2024)
Authors: Timothy Devos
Pages: 105 - 116 - Clinical outcomes of patients with myelofibrosis after immediate transition to momelotinib from ruxolitinib.(2024)
Authors: Timothy Devos
Pages: 1 - 12 - Predictors for improvement in patient-reported outcomes: post hoc analysis of a phase 3 randomized, open-label study of eculizumab and ravulizumab in complement inhibitor-naive patients with paroxysmal nocturnal hemoglobinuria(2024)
Authors: Timothy Devos
Pages: 5 - 15 - Exploring the relationship between anellovirus load and clinical variables in hospitalized COVID-19 patients: Implications for immune activation and inflammation(2023)
Authors: Marijn Thijssen, Timothy Devos, Geert Meyfroidt, Marc Van Ranst, MahmoudReza Pourkarim
Pages: 49 - 54 - MANIFEST: Pelabresib in Combination With Ruxolitinib for Janus Kinase Inhibitor Treatment-Naive Myelofibrosis(2023)
Authors: Timothy Devos
Pages: 4993 - + - Transform-1: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, International Phase 3 Study of Navitoclax in Combination with Ruxolitinib Versus Ruxolitinib Plus Placebo in Patients with Untreated Myelofibrosis(2023)
Authors: Timothy Devos
- Modulation of TGF-β Superfamily Signaling By Ker-050 Demonstrated Potential to Treat Myelofibrosis and Mitigate Ruxolitinib-Associated Cytopenia(2023)
Authors: Timothy Devos
- Impact of Cytoreductive Drugs upon Outcomes in a Contemporary Cohort of Adolescent and Young Adults with Essential Thrombocythemia and Polycythemia Vera(2023)
Authors: Timothy Devos
- Germline heterozygous SH2B3-mutations and (idiopathic) erythrocytosis: Detection of a previously undescribed mutation.(2023)
Authors: Gaël Vermeersch, Timothy Devos
Pages: 1143 - 1147